Should tamiflu be offered to critically ill patients. Please evaluate most recent study REMAP-CAP and other studies

Comment by InpharmD Researcher

The Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) guidelines, which predate the 2026 REMAP-CAP trial, recommend oseltamivir for hospitalized patients with severe influenza, emphasizing initiation as soon as possible, preferably within 48 hours of symptom onset. Following REMAP-CAP, UK guidance continues to recommend oseltamivir as first-line treatment for critically ill patients, while Australian guidance strongly recommends against its use in critically ill patients aged >12 years. The REMAP-CAP trial enrolled 442 critically ill patients and found no mortality benefit, with a signal of increased 90-day mortality compared with no antiviral treatment, prompting early termination of the treatment arms. However, patients had experienced symptoms for a median of 5 days before randomization, leaving uncertainty about earlier treatment initiation, with findings from the ongoing RECOVERY trial awaited to further clarify oseltamivir's safety and effectiveness. In contrast, observational studies have generally associated oseltamivir with reduced mortality in critically ill adults, particularly when initiated within 48 hours, although benefits have also been reported with later initiation. Overall, the REMAP-CAP findings raise concerns about oseltamivir use in critically ill patients and its implications for clinical practice, although uncertainties surrounding treatment timing and conflicting observational evidence underscore the need for further randomized evidence.

PubMed and Google Scholar were searched using combinations of “oseltamivir,” “Tamiflu,” “severe influenza,” “critically ill,” “intensive care,” and “REMAP-CAP” to identify clinical trials, observational studies, systematic reviews, and meta-analyses evaluating efficacy, safety, treatment timing, dosing, and duration. CDC, WHO, UK, and Australian guidance and the REMAP-CAP preprint were also reviewed; five primary studies were included in the literature review.

Background

A 2026 Centers for Disease Control and Prevention (CDC) clinician summary recommends initiating oral or enterically administered oseltamivir as soon as possible in all hospitalized patients with suspected or confirmed influenza, without awaiting laboratory confirmation; observational evidence indicates that benefit is greatest with early treatment but may persist when treatment is initiated more than 48 hours after symptom onset. At the time, no sufficiently powered, randomized, placebo-controlled trials of neuraminidase inhibitor monotherapy had been completed in hospitalized patients; however, observational studies have associated treatment with shorter hospitalization and reduced risks of intensive care unit (ICU) transfer, invasive mechanical ventilation, or death, although some studies have not demonstrated a mortality reduction. Standard-dose oseltamivir achieves therapeutic concentrations in critically ill adults, including limited data involving administration through gastric tubes and use during continuous renal replacement therapy or extracorporeal membrane oxygenation, whereas available evidence does not indicate additional clinical benefit from higher dosing. The optimal treatment duration in severe or complicated influenza remains uncertain; longer treatment may be considered for patients who remain severely ill after 5 days or have prolonged lower respiratory tract viral replication, with decisions guided by clinical judgment and, when appropriate, lower respiratory tract RT-PCR testing. Inhaled zanamivir, intravenous peramivir, and oral baloxavir are not routinely recommended for hospitalized patients because clinical-benefit data are insufficient, and adding baloxavir to a neuraminidase inhibitor did not improve time to clinical improvement in one randomized trial. [1]

The 2024 World Health Organization (WHO) clinical practice guideline conditionally recommends oseltamivir for patients with suspected or confirmed severe influenza, including infections caused by novel influenza A viruses associated with high mortality or an unknown risk of severe disease, based on very-low-quality evidence; treatment should be initiated as early as possible and within 2 days of symptom onset. Evidence was derived from 2 randomized controlled trials involving 104 patients with severe influenza and indicated that oseltamivir may reduce hospitalization duration by 1.63 days versus standard care or placebo (95% confidence interval [CI] 0.45 to 2.81 days fewer; low-certainty evidence), whereas its effects on seasonal influenza mortality (risk ratio [RR] 0.53; 95% CI 0.07 to 4.24) and intensive care unit admission were very uncertain. The recommended adult dosage is 75 mg orally twice daily for 5 days, with renal dose adjustment as indicated; longer treatment may be considered for severe or zoonotic influenza and in immunocompromised patients. Oseltamivir may be administered enterically through an orogastric or nasogastric tube in intubated patients and is well absorbed by this route, but the guideline identifies malabsorption, gastric stasis, ileus, and gastrointestinal bleeding as contraindications to enteric administration. [2]

The October 2026 UK Health Security Agency (UKHSA) guidance on the use of antiviral agents for the treatment and prophylaxis of seasonal influenza continues to recommend oseltamivir as first-line treatment for patients with severe influenza, including those who are critically ill. The guidance emphasizes that antiviral treatment provides the greatest benefit when initiated within 48 hours of symptom onset, although treatment initiated up to 5 days after symptom onset may still be beneficial. Notably, the guidance acknowledges preliminary findings from the 2026 REMAP-CAP trial, which demonstrated no mortality benefit and reported higher mortality with oseltamivir compared with no antiviral treatment in critically ill patients, leading to early termination of the oseltamivir treatment arms. However, the guidance notes that treatment was initiated a median of 5 days after symptom onset, limiting generalizability to patients treated earlier, and identifies additional evidence gaps involving cause-specific mortality, influenza subtypes, and viral load. When oseltamivir cannot be administered promptly or is unsuitable, alternative treatments, including baloxavir or zanamivir, may be considered under specialist guidance, although supporting clinical evidence remains limited. The guidance states that treatment recommendations will continue to be reviewed as additional REMAP-CAP data and results from ongoing randomized trials, including the RECOVERY trial, which continues to enroll critically ill patients for randomization to oseltamivir monotherapy, become available. [3]

Interestingly, the October 2026 Australian Living Evidence Collaboration guideline provides a strong recommendation against oseltamivir in critically ill adults aged >12 years with confirmed or suspected influenza, regardless of symptom duration, including those who are immunocompromised, pregnant, experiencing shock, or have bacterial coinfection. The guideline also recommends discontinuing oseltamivir in patients who develop critical illness during treatment. These recommendations are based on the REMAP-CAP trial, which demonstrated no clinical benefit and suggested an increased risk of mortality with oseltamivir compared with standard care alone (moderate-certainty evidence). For children aged ≤12 years with influenza-associated respiratory failure, the guideline conditionally recommends against oseltamivir, citing a lack of direct pediatric evidence and potential harm suggested by adult data (low-certainty evidence). However, oseltamivir may be considered on a case-by-case basis for critically ill children with nonrespiratory manifestations, such as encephalopathy or myocarditis, following specialist consultation. [4]

A 2025 narrative review evaluating antiviral therapy for critically ill patients with influenza reported that no randomized controlled trials have specifically assessed oseltamivir in this population; however, six prospective or retrospective observational studies consistently associated early oseltamivir administration with improved survival or reduced mortality. International guidelines recommend initiating oseltamivir as soon as possible in hospitalized patients with severe influenza, including when illness has been present for more than 48 hours, although the strength and quality of supporting evidence vary. The usual recommended regimen is 75 mg twice daily for 5 days, adjusted for renal impairment; extending treatment to 10 days may be reasonable in immunocompromised patients or those with persistent symptoms and viral shedding at day 5, whereas higher-dose oseltamivir (150 mg twice daily) has not demonstrated faster viral-load reduction or clinical superiority. The review also noted limited and variable pharmacokinetic data in critically ill patients and emphasized that persistent viral replication, particularly among immunocompromised patients, may promote oseltamivir resistance and warrant resistance testing and consideration of an alternative antiviral. [5]

A 2024 network meta-analysis evaluated 8 randomized controlled trials involving 1,424 hospitalized patients with severe suspected or laboratory-confirmed influenza, with 6 trials included in the network meta-analysis. Compared with placebo or standard care, oseltamivir might reduce hospitalization duration (3.37 vs 5.00 days; mean difference [MD] −1.63 days; 95% CI −2.81 to −0.45; low-certainty evidence) but demonstrated little or no difference in time to symptom alleviation (MD 0.34 days; 95% CI −0.86 to 1.54; low-certainty evidence). The effect of oseltamivir on mortality was very uncertain (risk ratio [RR] 0.53; 95% CI 0.07 to 4.24; very-low-certainty evidence), and uncertainty remained regarding ICU admission, progression to mechanical ventilation, and other clinically important outcomes. The included trials did not report treatment timing relative to symptom onset, precluding evaluation of early versus delayed oseltamivir initiation. [6]

A 2014 individual-participant-data meta-analysis of 78 observational studies evaluated neuraminidase inhibitor treatment and mortality among 29,234 patients hospitalized with pandemic influenza A(H1N1)pdm09, including 6,828 patients admitted to critical care; oral oseltamivir accounted for 92% of reported neuraminidase inhibitor use. Among critically ill adults, treatment at any time was associated with lower mortality versus no treatment (adjusted odds ratio [OR] 0.72; 95% CI 0.56 to 0.94), while treatment initiated within 2 days of symptom onset was associated with lower mortality versus later treatment (adjusted OR 0.62; 95% CI 0.49 to 0.77) and no treatment (adjusted OR 0.31; 95% CI 0.20 to 0.47). Treatment initiated more than 2 days after symptom onset was also associated with lower mortality versus no treatment in critically ill adults (adjusted OR 0.65; 95% CI 0.46 to 0.93); corresponding associations were not statistically significant in critically ill children. The authors advocated early neuraminidase inhibitor treatment in adults hospitalized with suspected or confirmed influenza but acknowledged the observational design, inability to adjust specifically for disease severity, potential residual confounding, and missing treatment-exposure data. [7]

Background References: [1] Centers for Disease Control and Prevention. Influenza Antiviral Medications: Summary for Clinicians. March 10, 2026. Accessed August 17, 2026.
[2] World Health Organization (WHO). Clinical practice guidelines for influenza. September 12, 2024. Accessed August 17, 2026.
[3] UK Health Security Agency. Guidance on Use of Antiviral Agents for the Treatment and Prophylaxis of Seasonal Influenza. Updated October 23, 2026. Accessed October 27, 2026. https://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents/guidance-on-use-of-antiviral-agents-for-the-treatment-and-prophylaxis-of-seasonal-influenza
[4] Australian Living Evidence Collaboration. Drug Treatments for People With Influenza Who Are Critically Ill: Australian Guideline. Version 1.2. Updated October 12, 2026. Accessed October 27, 2026. https://livingevidence.org.au/influenza/
[5] Bay P, Martin-Loeches I, Haudebourg AF, et al. How to manage antivirals in critically ill patients with influenza?. Clin Microbiol Infect. 2025;31(7):1157-1165. doi:10.1016/j.cmi.2025.04.002
[6] Gao Y, Guyatt G, Uyeki TM, et al. Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2024;404(10454):753-763. doi:10.1016/S0140-6736(24)01307-2
[7] Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2(5):395-404. doi:10.1016/S2213-2600(14)70041-4
Literature Review

A search of the published medical literature revealed 5 studies investigating the researchable question:

should tamiflu be offered to critically ill patients. Please evaluate most recent study REMAP-CAP and other studies

Level of evidence

B - One high-quality study or multiple studies with limitations  Read more→



Please see Tables 1-5 for your response.


 

Oseltamivir for Critically Ill Patients with Influenza: A Randomised Trial
Design

Randomized controlled trial

N= 442

Objective To evaluate the efficacy of oseltamivir in critically ill patients with influenza
Study Groups

Oseltamivir x 5 days (n= 162)

Oseltamivir x 10 days (n= 156)

No antiviral (n= 124)

Inclusion Criteria Critically ill patients aged ≥ 12 years old with confirmed influenza infection requiring intensive care unit (ICU) admission
Exclusion Criteria Patients with contraindications to oseltamivir, those who had received more than 48 hours of antiviral therapy prior to enrollment, imminent death expected within 24 hours
Methods

Patients were randomly assigned to receive one of two dosing regimens of oseltamivir or no antiviral. Oseltamivir was dosed at 75 mg administered enterally twice daily for 5 or 10 days. Treatment was continued until discharge or completion of 5 or 10 day treatment course, whichever came first. 

Duration Follow-up period of 90 days
Outcome Measures

Primary: Mortality at 90 days

Secondary: Duration of hospital and ICU stay, duration of mechanical ventilation

Baseline Characteristics
Baseline characteristic 5-day oseltamivir (n=162) 10-day oseltamivir (n=156) No antiviral (n=124)
Age, years, median (IQR) 60 (49–70) 60 (51–70) 63 (51–71)
Female sex at birth 73 (45.1%) 63 (40.4%) 47 (37.9%)
Body mass index, median (IQR) 27 (24–34); n=129 27 (23–32); n=129 28 (23–31); n=116
APACHE II score, median (IQR) 15 (11–21); n=157 18 (12–25); n=148 16 (11–24); n=121
Influenza A 144/162 (88.9%) 138/156 (88.5%) 111/124 (89.5%)
Influenza B 10/162 (6.2%) 15/156 (9.6%) 8/124 (6.5%)
SARS-CoV-2 coinfection 1/162 (0.6%) 4/156 (2.6%) 3/124 (2.4%)
Symptoms before randomization, days, median (IQR) 5 (3–7); n=143 5 (3–7); n=129 5 (3–8); n=101
Received oseltamivir before randomization 81 (50.0%) 64 (41.0%) 40 (32.2%)
Clinical Frailty Scale, median (IQR) 3 (2–4); n=162 3 (2–4); n=155 3 (2–4); n=122
Invasive mechanical ventilation 77 (47.5%) 83 (53.2%) 48 (38.7%)
PaO₂/FiO₂ ratio, median (IQR) 166 (125–240); n=138 160 (110–228); n=138 178 (135–247); n=112
Vasopressor support 70 (43.2%) 86 (55.1%) 47 (37.9%)
ECMO 0/157 (0%) 2/150 (1.3%) 0/123 (0%)
Cardiovascular SOFA score, median (IQR) 1 (0–3); n=162 3 (0–4); n=155 1 (0–3); n=122
Lactate, mmol/L 1.5 (1.0–2.3); n=149 1.8 (1.2–3.1); n=143 1.5 (1.0–2.3); n=118
Creatinine, μmol/L 88 (71–150); n=157 97 (71–168); n=153 9 (62–150); n=119¹
eGFR, mL/min/1.73 m² 75.8 (41.8–100.2); n=157 71.2 (32.8–97.1); n=153 75.9 (38.4–100.8); n=119
Results
Outcome 5-day oseltamivir (n=162) 10-day oseltamivir (n=156) No antiviral (n=124) Comparative result vs no antiviral
Primary: 90-day all-cause mortality 32/162 (19.8%) 30/155 (19.4%) 17/124 (13.7%) Adjusted OR: 2.13 (95% CrI, 1.03–4.52) and 2.17 (1.05–4.64), respectively
Survival time through day 90 - - Reference Adjusted HR: 1.35 (0.72–2.49) and 1.29 (0.67–2.43), respectively
Organ support-free days through day 28, median (IQR) 22 (0.5–26) 21 (0–25.5) 23 (12.75–27) Adjusted OR: 1.28 (0.78–2.11) and 1.33 (0.80–2.21)
Disease progression among patients not invasively ventilated at baseline¹ 23/85 (27.1%) 13/73 (17.8%) 15/76 (19.7%) Adjusted OR: 2.53 (0.92–7.26) and 1.65 (0.52–4.98)
ICU-free days Not reported descriptively Not reported descriptively Reference Adjusted HR: 1.20 (0.88–1.65) and 1.18 (0.85–1.64)
Hospital-free days Not reported descriptively Not reported descriptively Reference Adjusted HR: 1.12 (0.82–1.53) and 1.07 (0.78–1.48)
Adverse Events

Common Adverse Events: Nausea (15% vs. 10%); vomiting (8% vs. 5%)

Serious Adverse Events: No significant difference between groups

Study Author Conclusions Oseltamivir did not significantly reduce mortality at 90 days in critically ill patients with influenza, but it was associated with a reduction in the duration of ICU stay and mechanical ventilation.
Critique The study was well-designed with a robust randomization process, but the lack of significant mortality benefit may limit its impact. The study's strengths include a large sample size and comprehensive data collection. However, the exclusion of patients who had received prior antiviral therapy may limit the generalizability of the findings to all critically ill influenza patients.
Table 1 References:
[8] REMAP-CAP Investigators. Oseltamivir for critically ill patients with influenza: a randomised trial. SSRN. Preprint published online July 27, 2026. doi:10.2139/ssrn.7172531

 

Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial
Design

Randomised, parallel-group, double-blind, placebo-controlled, superiority trial

N= 366

Objective To test whether combining the cap-dependent endonuclease inhibitor baloxavir marboxil with standard-of-care neuraminidase inhibitors would result in improved clinical outcomes compared with neuraminidase inhibitor monotherapy in hospitalised patients with severe influenza
Study Groups

Baloxavir group (n= 241)

Control group (n= 125)

Inclusion Criteria Patients aged 12 years or older who were hospitalised with laboratory-confirmed influenza and had a National Early Warning Score 2 (NEWS2) of 4 or greater
Exclusion Criteria Patients weighing less than 40 kg, expected to be discharged or die within 48 h, or who had received antiviral treatment for 48 h or longer before screening
Methods Patients were randomly assigned to receive either baloxavir plus neuraminidase inhibitors (NAIs) or placebo plus NAIs. Baloxavir was administered orally on day 1 and day 4 (40 mg for bodyweight <80 kg, or 80 mg for ≥80 kg), and on day 7 if no clinical improvement had occurred by day 5. NAIs included oseltamivir, zanamivir, and peramivir, administered according to local standard practice. The primary endpoint was time to clinical improvement, defined as time to a NEWS2 of 2 or lower for 24 h or hospital discharge, whichever came first
Duration January 8, 2019, to March 16, 2020
Outcome Measures

Primary: Time to clinical improvement S

Secondary: Safety analyses

Baseline Characteristics   Baloxavir group (n= 208)* Control group (n= 114)*
Age, years  59.4 ± 19.6 61.9 ± 19.9
Female 99 (48%) 53 (46%)
Asian 39 (19%) 21 (18%)
White 151 (73%) 86 (75%)
Current influenza episode 197 (95%) 107 (94%)
Requires ventilation or supplemental oxygen 143 (69%) 80 (70%)
NEWS2 at baseline  6.72 ± 2.25 6.69 ± 2.33

Antiviral treatment ≤48 h before screening**

Oseltamivir/oseltamivir

Peramivir 

Laninamivir octanoate

 

64/76 (84%)*

11/76 (14%)*

1/76 (1%)*

 

39/46 (85%)*

7/46 (15%)*

0/46* 

*The modified intention-to-treat infected (mITTI) population (ie, all patients who were randomly assigned to treatment, received a dose of study drug, and were RT-PCR-positive for influenza at any timepoint according to the treatment assigned at randomisation) 

**As a proportion of patients who received antiviral treatment within 48 h before screening. 

Prior antiviral use within 48 hours before screening was similar between groups, occurring in 37% of patients in the baloxavir group and 40% in the control group, with oseltamivir being the most commonly used antiviral. Among patients receiving baloxavir, 78% received two doses, 16% received three doses, and 6% received one dose. Baseline demographic and clinical characteristics were generally similar between treatment groups.

Results   Baloxavir group (n= 208) Control group (n= 114) p-value
Median time to clinical improvement, hours (95% CI) 97.5 (75.9-117.2) 100.2 (75.9-144.4) 0.467
Median time to cessation of viral shedding, hours (95% CI) 23.9 (23.2-24.5) 63.7 (46.4-68.1) <0.0001

Among 322 patients in the modified intent-to-treat infected population (mITTI), 208 received baloxavir and 114 received control, with 87% having influenza A. Median time to clinical improvement was similar between groups (97.5 vs 100.2 hours, median difference −2.7 hours, 95% CI −53.4 to 25.9, P=0.467). Baloxavir plus a NAI was well tolerated, with serious adverse events occurring in 12% vs 15% of patients, respectively. Mortality was 2% with baloxavir compared with 6% with control, with no deaths considered treatment-related.

Adverse Events Baloxavir plus NAI was well tolerated, with no new safety signals observed. Serious adverse events occurred in 12% of patients in the baloxavir group versus 15% in the control group. One serious adverse event (orthostatic hypotension) was considered related to treatment in the control group.
Study Author Conclusions Combining baloxavir with NAIs did not result in superior clinical outcomes compared with NAIs alone. The combination was well tolerated, suggesting that combination antivirals would not be routinely indicated in clinical practice for hospitalised patients with severe influenza
Critique The study was well-designed as a double-blind, placebo-controlled trial, providing robust data on the efficacy and safety of combining baloxavir with NAIs. However, the lack of significant clinical improvement with combination therapy suggests limited benefit over standard NAI treatment. The study's limitations include the inability to assess the effect of baloxavir monotherapy and the potential impact of late treatment initiation. Additionally, the study did not evaluate the efficacy of the combination against influenza B due to the limited number of such cases in the cohort.
Table 2 References:
[9] Kumar D, Ison MG, Mira JP, et al. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. Lancet Infect Dis. 2022;22(5):718-730. doi:10.1016/S1473-3099(21)00469-2

 

Effectiveness of prolonged versus standard‐course of oseltamivir in critically ill patients with severe influenza infection: A multicentre cohort study
Design

Retrospective cohort study of prospectively collected data

N= 2397

Objective To investigate the effectiveness of prolonged versus standard‐course oseltamivir treatment among critically ill patients with severe influenza
Study Groups

Prolonged oseltamivir (n= 1943)

Standard oseltamivir (n= 454)

Inclusion Criteria Adults with severe acute respiratory infection and acute respiratory failure requiring ICU admission, microbiological confirmation of influenza A or B virus infection by rt-PCR, and received oseltamivir at ICU admission for at least 5 days
Exclusion Criteria Children younger than 15 years old, subjects with missing data on antiviral therapy or ICU survival, and patients with ICU length of stay less than 5 days
Methods Retrospective analysis of a database including adults with influenza infection admitted to 184 ICUs in Spain from 2009 to 2018. Prolonged oseltamivir was defined as treatment beyond 5 days, standard as 5 days. Propensity score matching was used to control for confounding factors. Primary outcome was all-cause ICU mortality, analyzed through Cox regression and RCSs.
Duration 2009 to 2018
Outcome Measures

Primary: All-cause ICU mortality

Secondary: Differences in ICU length of stay and duration of invasive mechanical ventilation

Baseline Characteristics   Total (N = 2397) Prolonged Oseltamivir (n= 1943) Standard Oseltamivir (n = 454) p Value
Age (years) 56 (44–67) 54 (43–66) 61 (50–72) <0.001
Male 1458 (60.8%) 1176 (60.5%) 282 (62.5%) 0.57
APACHE II score 16 (12–22) 16 (12–21) 18 (14–24) <0.001
SOFA score 6 (4–8) 6 (4–8) 6 (4–9) 0.51
Pulmonary infiltrates in chest X-ray >2 1240 (51.7%) 1033 (53.2%) 207 (45.6%) 0.004
Type of influenza virus A(H1N1) 1691 (70.5%) 1458 (75%) 233 (51.3%) <0.001
Obesity 779 (32.5%) 647 (33.3%) 132 (29.1%) 0.09
Chronic obstructive pulmonary disease 555 (23.2%) 422 (21.7%) 133 (29.3) <0.001
Immunosuppression 370 (15.4%) 291 (15%) 79 (17.4%) 0.22
Pneumonia 2108 (87.9%) 1742 (89.7%) 366 (80.6%) <0.001
Results   Prolonged Oseltamivir (n= 1943) Standard Oseltamivir (n= 454) p-value
ICU mortality 387 (22.1%) 119 (28.3%) 0.009
ICU length of stay, days (IQR) 14 (8–25) 8 (6–14) <0.001
Duration of mechanical ventilation, days (IQR) 14 (9–23) 9 (5–16) <0.001
Adverse Events Not specifically reported
Study Author Conclusions Prolonged oseltamivir was associated with reduced ICU mortality in critically ill patients with severe influenza. Clinicians should consider extending the oseltamivir treatment duration to 10 days, particularly in higher-risk groups of prolonged viral shedding.
Critique The study's strengths include a large sample size and the use of propensity score matching to control for confounding factors. However, limitations include its retrospective design, lack of monitoring for viral shedding duration, and potential for selection bias. The study was conducted in Spain, which may limit generalizability to other regions. Additionally, the cost implications of prolonged treatment were not fully explored.
Table 3 References:
[10] Moreno G, Carbonell R, Daz E, et al. Effectiveness of prolonged versus standard-course of oseltamivir in critically ill patients with severe influenza infection: A multicentre cohort study. J Med Virol. 2023;95(8):e29010. doi:10.1002/jmv.29010

 

Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial
Design

Double blind randomised trial

N= 326

Objective To investigate the validity of recommendations in treatment guidelines to use higher than approved doses of oseltamivir in patients with severe influenza
Study Groups

Double dose oseltamivir (n= 165)

Standard dose oseltamivir (n= 161)

Inclusion Criteria Patients aged ≥1 year admitted to hospital with confirmed severe influenza
Exclusion Criteria Pregnancy or positive for chorionic gonadotrophin (hCG) in urine, women who were actively breast feeding, a delay of more than 72 hours before treatment with oseltamivir, and severe renal impairment defined by creatinine clearance <10 mL/min
Methods Patients were randomised to receive double dose (150 mg twice a day or paediatric equivalent) or standard dose (75 mg twice a day or paediatric equivalent) oseltamivir. Treatment was supervised by the research team and continued for five days, with an additional five days for those meeting clinical failure criteria
Duration April 2007 to February 2010
Outcome Measures

Primary: Proportion of patients with no detectable viral RNA by RT-PCR on day five

Secondary: Mortality, mechanical ventilation, admission to intensive care, symptoms, resumption of activity

Baseline Characteristics

At enrollment, the study included 246 children and 80 adults randomized to double-dose or standard-dose oseltamivir. Baseline characteristics were generally similar between treatment groups within both age populations. Children had a mean age of 2.8 years and had been ill for approximately 5 days, while adults had mean ages of 37.9 years in the double-dose group and 45.9 years in the standard-dose group and approximately 5 days of illness. Cough was nearly universal in both populations, while dyspnea, tachypnea, and fever were also common. Adults had a greater burden of severe illness and comorbidities, including lower Karnofsky scores, hypertension, and alcoholism, and were more likely to have received antivirals before enrollment (63–67% vs 10% of children).

Radiographic infiltrates were common in both children and adults (77–79% and 90–95%, respectively), while acute respiratory distress syndrome (ARDS) was more frequent in adults (19.5–25.6% vs 2.4–3.3% in children). Adults also more frequently required intensive care, supplemental oxygen, and mechanical ventilation. Viral subtypes varied across groups, with H3N2 predominating in children and H1N1-pdm09 and H3N2 commonly identified in adults.

Results

The primary virological endpoint showed no significant difference between double- and standard-dose oseltamivir. On day 5, viral RNA was undetectable in 72.3% of patients receiving double-dose compared with 68.2% receiving standard-dose oseltamivir (difference 4.2%, 95% CI −5.9% to 14.2%, p=0.42), with similar findings in children and adults and across influenza subgroups. Viral shedding continued to decline after day 5, with no meaningful differences between treatment groups through day 14. Day 5 clinical failure also did not differ significantly between groups (9.9% vs 13%, p=0.44).

Overall mortality was 6.4%, with similar rates between double- and standard-dose groups (7.3% vs 5.6%, p=0.54), and most deaths occurred in patients with H5N1 influenza. Requirements for supplemental oxygen, intensive care, and mechanical ventilation, as well as their durations, were similar between groups. No H275Y resistance mutations were detected in H1N1-pdm09 or H5N1 infections. Among patients with seasonal H1N1, the H275Y mutation was present at baseline in 56% of sequenced samples, and some patients developed the mutation during treatment, predominantly in the standard-dose group, although no clear differences in viral clearance or clinical outcomes were observed.

Adverse Events Oseltamivir was generally well tolerated; 55 (16.9%) patients had 75 treatment emergent adverse events with similar rates between the two arms. The most common adverse events were respiratory failure, diarrhoea, and multi-organ failure. Overall 14 (19%) adverse events were judged as possibly, probably, or definitely related to oseltamivir. 
Study Author Conclusions There were no virological or clinical advantages with double dose oseltamivir compared with standard dose in patients with severe influenza admitted to hospital.
Critique The study was well-designed as a double-blind randomised controlled trial, providing robust evidence. However, the study was not powered for subgroup analyses, and the heterogeneous population characteristics may limit the generalizability of the findings. Additionally, the study was not placebo-controlled, which could have provided more definitive conclusions on the efficacy of oseltamivir in severe influenza
Table 4 References:
[11] South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ. 2013;346:f3039. Published 2013 May 30. doi:10.1136/bmj.f3039
The association of empirical treatment with oseltamivir with the outcome of critically ill patients admitted with severe acute respiratory illness (SARI)
Design

Multicenter retrospective cohort study

N= 456

Objective To evaluate the association between empirical treatment with oseltamivir and the outcome of critically ill patients with Severe Acute Respiratory Infection (SARI) admitted to the Intensive Care Unit (ICU)
Study Groups

Oseltamivir (n= 301)

No oseltamivir (n= 155)

Inclusion Criteria Adult patients with SARI from September 2012 to December 2018
Exclusion Criteria Patients aged <14 years, diagnosed with MERS-CoV, labeled as comfort care or Do-Not-Resuscitate status, or with incomplete medical records
Methods Patients in the oseltamivir group received empirical treatment upon admission to the emergency department or ICU, with influenza testing, treatment continuation or discontinuation, and treatment duration determined by the treating physicians. Influenza testing was performed using real-time polymerase chain reaction (PCR), with additional multiplex PCR testing at the treating team's discretion. 
Duration September 2012 to December 2018
Outcome Measures

Primary: 90-day mortality

Other: Requirement of rescue oxygen therapy, hospital length of stay

Baseline Characteristics   Oseltamivir (n= 301) No oseltamivir (n= 155)
Age, years (IQR) 69 (49, 78) 70 (54, 79)
Male 173 (57.5%) 87 (56.1%)
Body mass index, Kg/m2 (IQR) 28 (24,33.0) 27 (22.5,32)
SOFA score (IQR) 7 (4, 9) 7 (5, 10)

Abbreviations: IQR, interquartile range.

Of the 456 patients included, 334 (73%) underwent influenza testing, of whom 87 (26%) had laboratory-confirmed influenza.

Results   Oseltamivir (n= 301) No oseltamivir (n= 155) p-value
90-day mortality 81 (26.9%) 48 (31.0%) 0.36
Hospital length of stay, days (IQR) 20 (12, 35) 27 (12, 68) 0.01
Rescue oxygen therapy 69 (22.9%) 54 (34.8%) 0.007
Adverse Events Not assessed
Study Author Conclusions In the critically ill population, there remain many debates regarding the clinical benefit of oseltamivir based on initiation time, dosing, and duration of therapy. Our study adds to the existing observational data on the effectiveness of late initiation of oseltamivir in critically ill patients. These findings demonstrate that among patients with SARI admitted to the ICU, empirical oseltamivir was associated with lower mortality. Hence, it may be prudent to initiate oseltamivir therapy empirically in all critically ill patients with community-acquired pneumonia during the influenza season, regardless of symptom duration and without awaiting laboratory confirmation. Future research on the optimal timing of oseltamivir in SARI is warranted.
Critique The study's strengths included its relatively large sample size and detailed clinical data collected across seven influenza seasons. Limitations included its retrospective observational design, potential unmeasured confounding, indication bias, and possible inaccuracies from medical record reviews. Additionally, the study included patients with severe acute respiratory illness rather than exclusively confirmed influenza, with only 87 patients testing positive for influenza and just 2 of these patients in the untreated group, limiting comparisons specifically among patients with confirmed influenza.
Table 5 References:
[12] Khan RM, AlMarashi LM, Temsah MH, et al. The association of empirical treatment with oseltamivir with the outcome of critically ill patients admitted with severe acute respiratory illness (SARI). SAGE Open Med. 2026;14:20503121261478401. Published 2026 Aug 13. doi:10.1177/20503121261478401